AbMax Biotechnology Co., Ltd. was established in 2006 and now is a high-tech enterprise and training base for the national life science and technical personnel. AbMax has the world’s most advanced one-stop technology platform for antibodies and kits researching, which has the monoclonal antibody developed in an average of 46 days with a high success rate of 90%. Moreover, AbMax is also the fastest, best and most competitive service provider of antibody developing in China and one of the world’s best service providers of antibody developing.
AbMax, as a member of biomedical field in the capital scientific and technological condition platform, is the training base of BeijingNormalUniversity and also joins the Alliance of Bio-Box Outsourcing, China (ABO). AbMax has 300 square meters of office and 1200 square meters of experimental base, including the cell biology laboratory, the molecular biology laboratory, the biochemistry laboratory, the animal laboratory facilities in line with AAALAC and the GMP workshop of diagnostic reagents.
After passing the ISO9001:2008 Quality Management System Certificate in 2009, AbMax has stepped a higher level in the technical service and the management of production quality and greatly improved its competitiveness.
In the past six years, AbMax provided services for a number of multinational pharmaceutical companies, the domestic and foreign well-known research units and bio-pharmaceutical enterprises and successfully developed thousands of high quality monoclonal antibodies for the antibody drug, protein, peptide, pathogens, small molecules and other antigens and dozens of kits. AbMax also undertook a dozen government major research projects and established the largest pathogen antibody library for emerging/outbreaking infectious diseases in China.
AbMax’s research team, led by Chinese-American scientist and entrepreneur, Dr. Sun Le, all have a bachelor degree or above, including 4 doctors and 8 masters.See more